Alumis Inc. ALMS 深 沪
等待开盘 11-04 09:30:00 美东时间
4.56
-0.190
-4.00%
华盛通- 最 高4.75
- 今 开4.71
- 成交量 84.29万股
- 最 低 4.385
- 昨 收 4.75
- 总市值 4.74亿
- 52周最高 12.29
- 市盈率 静 --
- 换手率 0.81%
- 52周最低 2.7601
- 委 比 2.16%
- 总股本 1.04亿
- 历史最高 13.53
- 量 比 2.03
- 振 幅 7.68%
- 历史最低 2.7601
- 每 手 1
- 风险率 2.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
10-20 20:10
Agillence to Provide Inbound Logistics Optimization Software to Rivian Automotive
SOUTHFIELD, Mich., Oct. 9, 2025 /PRNewswire/ -- Agillence, Inc., an optimization company, today announced that Rivian Automotive, Inc. (NASDAQ: RIVN) has selected it to provide proprietary o...
10-10 00:05
Alumis Inc. Updates Corporate Presentation on Pipeline
Alumis Inc. ( ($ALMS) ) has shared an update. On September 3, 2025, Alumis Inc....
09-03 18:28
Alumis to Participate in Upcoming September Investor Conferences
Alumis Inc., a late-stage biopharma company, announced its participation in six investor conferences in September 2025 to discuss its targeted therapies for immune-mediated diseases. Company updates will be shared at events including the Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, H.C. Wainwright Global Investment Conference, Baird Global Healthcare Conference, and Stifel Im...
08-29 11:00
Alumis Q2 Sales $2.67M Beat $2.00M Estimate
Alumis (NASDAQ:ALMS) reported quarterly sales of $2.67 million which beat the analyst consensus estimate of $2.00 million by 33.30 percent.
08-14 04:28
Alumis Inc. Concludes 2025 Annual Stockholders Meeting
The latest announcement is out from Alumis Inc. ( ($ALMS) ). On July 30, 2025, ...
08-05 04:41
Wall Street Analysts Are Bullish on Top Materials Picks
There’s a lot to be optimistic about in the Materials sector as 2 analysts just...
07-28 13:10
Alumis Completes Patient Enrollment In Global LUMUS Phase 2b Trial Of ESK-001, Next-Gen Oral Tyrosine Kinase 2 Inhibitor, For Treatment Of SLE; Topline Readout Expected In Q3 2026
Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its global
07-24 19:35
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
Alumis Inc. announced the completion of patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor, targeting systemic lupus erythematosus (SLE). The trial enrolled 408 patients and aims to assess disease activity improvements using the BICLA endpoint at Week 48. Topline data is expected in Q3 2026. ESK-001, designed to selectively target inflammatory drivers, has shown promising results in earlier st...
07-24 11:30
